Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia

Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate...

Full description

Saved in:
Bibliographic Details
Main Authors: Fatemeh Ensafi Talemi, Soudeh Ghafouri-Fard
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Leukemia Research Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048925000317
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849412857324634112
author Fatemeh Ensafi Talemi
Soudeh Ghafouri-Fard
author_facet Fatemeh Ensafi Talemi
Soudeh Ghafouri-Fard
author_sort Fatemeh Ensafi Talemi
collection DOAJ
description Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate response to this tyrosine kinase inhibitor. Recognition of the role of these transcripts in this process not only expands our knowledge about the molecular mechanisms of imatinib resistance, but also provides novel strategies for combating this phenotype. The current review summarizes the role of non-coding RNAs in this process and suggests novel candidates for further studies in this field to enhance therapeutic response to imatinib.
format Article
id doaj-art-e259e889e4d040b6a90809b4c3ccf16a
institution Kabale University
issn 2213-0489
language English
publishDate 2025-01-01
publisher Elsevier
record_format Article
series Leukemia Research Reports
spelling doaj-art-e259e889e4d040b6a90809b4c3ccf16a2025-08-20T03:34:19ZengElsevierLeukemia Research Reports2213-04892025-01-012410052910.1016/j.lrr.2025.100529Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemiaFatemeh Ensafi Talemi0Soudeh Ghafouri-Fard1Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author.Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases. Recently, it has been demonstrated that different classes of non-coding RNAs can modulate response to this tyrosine kinase inhibitor. Recognition of the role of these transcripts in this process not only expands our knowledge about the molecular mechanisms of imatinib resistance, but also provides novel strategies for combating this phenotype. The current review summarizes the role of non-coding RNAs in this process and suggests novel candidates for further studies in this field to enhance therapeutic response to imatinib.http://www.sciencedirect.com/science/article/pii/S2213048925000317lncRNAmiRNAcircRNAImatinibChronic myelogenous leukemia
spellingShingle Fatemeh Ensafi Talemi
Soudeh Ghafouri-Fard
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
Leukemia Research Reports
lncRNA
miRNA
circRNA
Imatinib
Chronic myelogenous leukemia
title Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
title_full Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
title_fullStr Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
title_full_unstemmed Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
title_short Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia
title_sort impact of non coding rnas on resistance to imatinib in chronic myelogenous leukemia
topic lncRNA
miRNA
circRNA
Imatinib
Chronic myelogenous leukemia
url http://www.sciencedirect.com/science/article/pii/S2213048925000317
work_keys_str_mv AT fatemehensafitalemi impactofnoncodingrnasonresistancetoimatinibinchronicmyelogenousleukemia
AT soudehghafourifard impactofnoncodingrnasonresistancetoimatinibinchronicmyelogenousleukemia